Skip to content

Connecting business. Building understanding. Advancing peace.

Insilico Medicine to Showcase AI Drug Discovery Platforms in Dubai and London

Biotechnology firm Insilico Medicine announced its leadership will present advancements in artificial intelligence drug discovery and laboratory robotics at conferences in Dubai and London. Co-Founder and President Dr. Alex Aliper is scheduled to deliver a keynote at Dubai Future Week on closed-loop AI and robotic laboratories. Founder and CEO Dr. Alex Zhavoronkov will participate in panels in London examining China's biopharmaceutical innovation sector.

Illustration: A modern automated biotechnology laboratory with precision robotic arms handling test tubes and microplates in an aseptic room, soft coo
Illustration

Biotechnology firm Insilico Medicine announced that its executive leadership will participate in international investor and technology gatherings in London and Dubai to present recent advancements in artificial intelligence-driven therapeutics and laboratory automation, according to Bioengineer.org. The scheduled presentations highlight how the combination of generative algorithms and automated robotics accelerates target discovery and candidate optimization.

In the United Arab Emirates, Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, will take part in Dubai Future Week, hosted by the Dubai Future Foundation. On November 20, Dr. Aliper is scheduled to deliver a keynote presentation titled "Generative AI and Laboratory Automation for Drug Discovery and Longevity," detailing the company's closed-loop architecture that combines proprietary generative AI algorithms with automated robotic laboratories.

In London, Dr. Alex Zhavoronkov, Founder and Chief Executive Officer of Insilico Medicine, has been invited to speak at the Jefferies Global Healthcare Conference 2026. Dr. Zhavoronkov will deliver a keynote address and join the China Biotech Panel on November 18 to discuss AI methodologies in pharmaceutical discovery and translational research in China's biopharmaceutical industry. He is also scheduled to take part in a China Biotech panel at the UBS Biopharma Conference on November 17.

Insilico Medicine, listed on the Main Board of the Hong Kong Stock Exchange under stock code 03696.HK, utilizes its Pharma.AI platform across disease areas including fibrosis, oncology, immunology, pain, and metabolic disorders, while expanding into materials, agriculture, nutrition, and veterinary sciences.

Sources

The UECN Brief

Policy updates, China–UAE business news and industry insights, delivered to your inbox.

Language
Subscriptions

Double opt-in: we send a confirmation link. Unsubscribe at any time. Privacy